Abstract:Targeted protein degradation (TPD) is emerging as a promising therapeutic approach for cancer and other diseases, with an increasing number of programs demonstrating its efficacy in human clinical trials. One notable method for TPD is Proteolysis Targeting Chimeras (PROTACs, or heterobifunctional degraders) that selectively degrade a protein of interest (POI) through E3-ligase induced ubiquitination followed by proteasomal degradation. PROTACs utilize a warhead-linker-ligand architecture to bring the POI (bound to the warhead) and the E3 ligase (bound to the ligand) into close proximity. The resulting non-native protein-protein interactions (PPIs) formed between the POI and E3 ligase lead to the formation of a stable POI-degrader-ligase ternary complex, enhancing cooperativity for TPD. A significant challenge in PROTAC design is the time-consuming and resource-intensive screening of the degrader linkers to induce favorable non-native PPIs between POI and E3 ligase. In this work, we present a physics-based computational protocol to systematically predict non-canonical and metastable PPI interfaces between an E3 ligase and a given POI, aiding in the design of linkers to stabilize the PROTAC ternary complex and enhance degradation. In our protocol, we build the non-Markovian dynamic model using the Integrative Generalized Master Equation (IGME) method from approximately 1.5 millisecond all-atom molecular dynamics (MD) simulations of linker-less encounter complex, to systematically explore the inherent PPIs between the oncogene homologue (KRAS) protein and the von Hippel-Lindau (VHL) E3 ligase. Our IGME model successfully revealed six metastable states each containing a different PPI interface. We selected three of these metastable states containing promising PPIs for linker design. Our selection criterion included the thermodynamic and kinetic stabilities of these PPIs and the accessibility of the linker to the solvent-exposed sites on the warheads and the E3 ligand. One of our selected PPIs closely matches a recent co-crystal PPI interface structure induced by an experimentally designed PROTAC with potent degradation efficacy. We anticipate that our IGME approach has significant potential for widespread application in predicting metastable POI-ligase encounter complex interfaces that can enable subsequent rational design of novel PROTACs.

Phthalimide Conjugations for the Degradation of Oncogenic PI3K

Development of small-molecule inhibitors that target PI3Kβ

Development of small-molecule inhibitors that target PI3K13

Developing selective PI3K degraders to modulate both kinase and non-kinase functions

Small Molecules Targeting Phosphoinositide 3-Kinases

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders

Targeted delivery of a PROTAC induced PDEδ degrader by a biomimetic drug delivery system for enhanced cytotoxicity against pancreatic cancer cells

Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future

Structure-based Rational Design Enables Efficient Discovery of a New Selective and Potent AKT PROTAC Degrader.

Synthesis and Sar of Novel 4-Morpholinopyrrolopyrimidine Derivatives As Potent Phosphatidylinositol 3-Kinase Inhibitors

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras

PROTACs: A novel strategy for cancer therapy

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders

Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile

Non-Markovian Dynamic Models Identify Non-Canonical KRAS-VHL Encounter Complex Conformations for Novel PROTAC Design

Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy